Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Research

• Publication date

  2000-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10667595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations

  2000cited by this paper
• Family history characteristics, tumor microsatellite instability and germline MSH2 and MLH1 mutations in hereditary colorectal cancer

  1999cited by this paper
• Treatment of cancer of the exocrine pancreas.

  1999cited by this paper
• Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.

  1999cited by this paper
• Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.

  1999cited by this paper
• Germline mutations of hMLH1 and hMSH2 genes in patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal cancer

  1998cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• The p16INK4a/CDKN2A tumor suppressor and its relatives.

  1998cited by this paper
• Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.

  1998cited by this paper
• Skin cancer prevention and screening: Summary of the American College of Preventive Medicine's practice policy statements

  1998cited by this paper
• Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee.

  1998cited by this paper
• CDKN2A mutations in multiple primary melanomas.

  1998cited by this paper
• [Chemotherapy for adenocarcinoma of the pancreas].

  1997cited by this paper
• BRCA2 mutations in hereditary breast and ovarian cancer in France.

  1997cited by this paper
• The CDKN2A (p16) Gene and Human Cancer

  1997cited by this paper
• Molecular basis of HNPCC: Mutations of MMR genes

  1997cited by this paper
• Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations.

  1997cited by this paper
• de la Chapelle, A.

  1997cited by this paper
• Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer.

  1997cited by this paper
• Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred.

  1997cited by this paper
• Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.

  1997cited by this paper
• Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients

  1997cited by this paper
• A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.

  1996cited by this paper
• Familial pancreatic cancer: a review.

  1996cited by this paper
• The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds

  1996cited by this paper
• Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

  1996cited by this paper
• Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes.

  1996cited by this paper
• Chemotherapy of adenocarcinoma of the pancreas.

  1996cited by this paper
• Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene

  1996cited by this paper
• Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

  1996cited by this paper
• Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer families

  1996cited by this paper
• Hereditary nonpolyposis colorectal cancer (Lynch syndrome): An updated review

  1996cited by this paper
• Epidemiology and risk factors in pancreatic cancer.

  1996cited by this paper
• BRCA1 mutations in a population-based sample of young women with breast cancer.

  1996cited by this paper
• Surgical management of pancreatic carcinoma.

  1996cited by this paper
• Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

  1996cited by this paper
• Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation

  1996cited by this paper
• Epidemiology and risk factors in pancreatic cancer

  1996cited by this paper
• Chemotherapy of adenocarcinoma of the pancreas.

  1996cited by this paper
• Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.

  1995cited by this paper
• Rapid detection of BRCA1 mutations by the protein truncation test

  1995cited by this paper
• Mutations associated with familial melanoma impair p16INK4 function

  1995cited by this paper
• Pancreatitis is a risk factor for pancreatic cancer.

  1995cited by this paper
• In vitro transcription/translation assay for the screening of hMLH1 and hMSH2 mutations in familial colon cancer.

  1995cited by this paper
• Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability

  1995cited by this paper
• A large multisite cancer family is linked to BRCA2.

  1995cited by this paper
• Epidemiology of and risk factors for pancreatic cancer.

  1995cited by this paper
• Trends in Cancer Incidence and Mortality

  1995cited by this paper
• Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.

  1995cited by this paper
• Pancreatic Cancer and Occupational Exposures

  1995cited by this paper
• Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer

  1994cited by this paper
• The tumor spectrum in HNPCC.

  1994cited by this paper
• A cell cycle regulator potentially involved in genesis of many tumor types.

  1994cited by this paper
• p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

  1994cited by this paper
• Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus

  1994cited by this paper
• Mutation of a mutL homolog in hereditary colon cancer.

  1994cited by this paper
• Neoplastic diseases in families of breast cancer patients.

  1994cited by this paper
• Family history and the risk of liver, gallbladder, and pancreatic cancer.

  1994cited by this paper
• Germline p16 mutations in familial melanoma

  1994cited by this paper
• Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families

  1994cited by this paper
• Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer

  1994cited by this paper
• Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

  1993cited by this paper
• The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

  1993cited by this paper
• How sensitive is PCR‐SSCP?

  1993cited by this paper
• Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.

  1993cited by this paper
• Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

  1993cited by this paper
• Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

  1993cited by this paper
• Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

  1993cited by this paper
• Familial Pancreatic Cancer: A Family Study

  1992cited by this paper
• The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC)

  1991cited by this paper
• Reported family aggregation of pancreatic cancer within a population-based case-control study in the francophone community in Montreal, Canada

  1991cited by this paper
• Familial cancer syndromes and clusters.

  1990cited by this paper
• Systemic cancer and the FAMMM syndrome.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Life-style risk factors for pancreatic cancer in Louisiana: a case-control study.

  1988cited by this paper
• Increased risk of cancer in the Peutz-Jeghers syndrome.

  1987cited by this paper
• Cancer in survivors of childhood soft tissue sarcoma and their relatives.

  1987cited by this paper
• Pancreas cancer and smoking, beverage consumption, and past medical history.

  1986cited by this paper
• Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study.

  1985cited by this paper

• Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future

  2025cites this paper
• The known genetic variants of BRCA1, BRCA2 and NOD2 in pancreatitis and pancreatic cancer risk assessment

  2025cites this paper
• Präventionsstrategien gastrointestinaler Tumoren

  2025cites this paper
• Therapeutic pancreatic cancer biomarkers and pharmacogenetics.

  2025cites this paper
• Pathogenic CDKN2A germline variants are rare in a cohort of unselected pancreatic cancer patients from Pakistan

  2025cites this paper
• Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer

  2024cites this paper
• Präventionsstrategien gastrointestinaler Tumoren

  2024cites this paper
• BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine

  2024cites this paper
• Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview

  2024cites this paper
• Bile Acids in Pancreatic Carcinogenesis

  2024cites this paper
• Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma

  2024cites this paper
• Pancreatic adenocarcinoma and aging: understanding the menace for better management

  2023cites this paper
• Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer

  2023cites this paper
• Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

  2023cites this paper
• Metabolic syndrome is linked to the incidence of pancreatic cancer

  2023cites this paper
• New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancreatic Cancer

  2022cites this paper
• Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer

  2022cites this paper
• Case 19-2022: A 29-Year-Old Woman with Jaundice and Chronic Diarrhea.

  2022cites this paper
• Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes

  2021cites this paper
• Curing Pancreatic Cancer.

  2021cites this paper
• BRCA mutations in pancreatic cancer and progress in their targeting

  2021cites this paper
• Targeting DNA damage repair pathways in pancreas cancer

  2021cites this paper
• PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer

  2021cites this paper
• Pancreatic cancer in 2021: What you need to know to win

  2021cites this paper
• Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

  2021cites this paper
• PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer

  2021cites this paper
• Diabetes Mellitus, Obesity, and Risk of Pancreatic Ductal Adenocarcinoma: a Large Case-Control Study from Iran

  2021cites this paper
• Inherited predisposition to pancreatic cancer.

  2021cites this paper
• Pancreatic Cancer Screening

  2021cites this paper
• BRCA-mutant pancreatic ductal adenocarcinoma

  2021cites this paper
• Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

  2021cites this paper
• Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma

  2021cites this paper
• PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

  2020influential citation
• DNA Damage Response Pathways in Cancer Predisposition and Metastasis

  2020cites this paper
• Pathophysiology of Pancreatic Adenocarcinoma

  2020cites this paper
• Germline genetic variability in pancreatic cancer risk and prognosis.

  2020cites this paper
• Dual malignancy: a rare presentation of synchronous periampullary carcinoma with renal cell carcinoma

  2020cites this paper
• Screening guidelines and recommendations for patients at high risk of developing endocrine cancers

  2020influential citation
• Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

  2020cites this paper
• Genetic testing for BRCA mutations: a policy paper

  2019cites this paper
• Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.

  2019cites this paper
• New therapeutic targets in pancreatic cancer.

  2019cites this paper
• Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.

  2019cites this paper
• Talking Genes in Breast and Pancreatic Malignancies

  2019cites this paper
• The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans

  2019cites this paper
• TRACKING TREATMENT RESPONSE AND RESISTANCE TO PARP INHIBITION (TALAZOPARIB) IN HEREDITARY PANCREATIC CANCER.

  2019cites this paper
• Screening patients at high risk for pancreatic cancer—Is it time for a paradigm shift?

  2019cites this paper
• Omics Approaches in Pancreatic Adenocarcinoma

  2019cites this paper
• Novel Targeted Treatment Approaches in Pancreatic Cancer

  2019cites this paper
• A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer.

  2019cites this paper
• The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer

  2019cites this paper
• Adenocarcinoma de pâncreas em paciente jovem: relato de caso

  2018cites this paper
• Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

  2018cites this paper
• Mutations in Known and Novel cancer Susceptibility Genes in Young Patients with Pancreatic Cancer.

  2018cites this paper
• Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA

  2018cites this paper
• Endoscopic Ultrasound–Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial

  2018cites this paper
• Pancreatic cancer as a sentinel for hereditary cancer predisposition

  2018cites this paper
• Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy

  2018cites this paper
• Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges

  2018cites this paper
• Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts

  2018cites this paper
• Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy

  2018influential citation
• Pathology: Premalignant and Malignant Diseases and Molecular Genetics

  2018cites this paper
• Морфологические особенности BRCA1‑ассоциированных опухолей

  2018cites this paper
• Current and Emerging Therapies in Pancreatic Cancer

  2018cites this paper
• CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer

  2018cites this paper
• First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report

  2018cites this paper
• Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer.

  2018cites this paper
• Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.

  2018cites this paper
• Cell cycle machinery and its alterations in pancreatic cancer

  2018cites this paper
• Multiple primary cancers in BRCA 1/2 carriers - A review of literature and our observations.

  2017cites this paper
• Aus der Klinik für Allgemein-, Viszeral- und Gefäßchirurgie der Medizinischen Fakultät Charité – Universitätsmedizin Berlin DISSERTATION Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor in pancreatic ductal adenocarcinoma

  2017cites this paper
• BRCA1 and BRCA2 Mutation in Pancreatic Cancer: Significance in Therapeutic Approach

  2017cites this paper
• Germline mutations in pancreatic cancer and potential new therapeutic options

  2017influential citation
• Genetisch bedingte Pankreaserkrankungen

  2017cites this paper
• Universal Panel Testing of Pancreatic Cancer Cases for Cancer Predisposition

  2017cites this paper
• Diagnosis and Management of Hereditary Pancreatic Cancer.

  2016cites this paper
• Prognostic and predictive markers in pancreatic adenocarcinoma.

  2016cites this paper
• Screening for Pancreatic Cancer in High-risk Populations.

  2016cites this paper
• Screening for Pancreatic Cancer.

  2016cites this paper
• Germline mutations in Japanese familial pancreatic cancer patients

  2016influential citation
• Interacción de los compuestos fenólicos del aceite de oliva virgen con las rutas de secelular

  2016cites this paper
• Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas

  2016cites this paper
• MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer

  2015cites this paper
• Novel targets in pancreatic cancer research.

  2015cites this paper
• Genetics of familial melanoma: 20 years after CDKN2A

  2015cites this paper
• Endoscopic ultrasound and pancreatic cancer: Advancing the application of technology for early detection

  2015cites this paper
• Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

  2015cites this paper
• Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

  2015cites this paper
• Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.

  2015cites this paper
• ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

  2015cites this paper
• Pathology of pancreatic tumors

  2015cites this paper
• Select Population-Based and Translational Research for Improving Pancreatic Cancer Early Detection

  2014cites this paper
• Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer

  2014cites this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cites this paper
• Genetic predisposition to pancreatic cancer.

  2014cites this paper
• Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma

  2014cites this paper
• Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

  2014cites this paper
• TOPIC HIGHLIGHT

  2014cites this paper
• A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

  2014cites this paper